In multiple sclerosis, treatment start or switch is prompted by evidence of disease activity.
Whilst immunomodulatory therapies reduce disease activity, the time required to attain
maximal effect is unclear. In this study we aimed to develop a method that allows
identification of the time to manifest fully and clinically the effect of multiple sclerosis
treatments ('therapeutic lag') on clinical disease activity represented by relapses and
progression-of-disability events. Data from two multiple sclerosis registries, MSBase …

Objective: To develop a method that allows identification of the time to full clinically manifest
effect of multiple sclerosis (MS) treatments ('therapeutic lag') on clinical disease activity.
Background: In MS, treatment start or switch is prompted by evidence of disease activity,
often presenting as relapses or disability progression. Whilst immunomodulatory therapies
reduce disease activity, the time required to attain maximal effect is unclear.
Design/Methods: Data from MSBase, a multinational MS registry, and OFSEP, the French …